Sean A. Mc Carthy Cytom X Therapeutics, Inc. (CTMX) insider trading activity

Sean A. Mc Carthy is CEO of CytomX Therapeutics, Inc.. Currently has a direct ownership of 1.09 Million shares of CTMX, which is worth approximately $3.74 Million. The most recent transaction as insider was on Jun 16, 2025, when has been sold 55,511 shares (Common Stock) at a price of $2.69 per share, resulting in proceeds of $149,324. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.09M

0% 3M change

65.64% 12M change

Total Value Held $3.74 Million

Sean A. McCarthy Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 16 2025	SELL Open market or private sale	$149,324 $2.69 p/Share	55,511 Reduced 4.85%	1,089,684 Common Stock
Jun 13 2025	BUY Exercise of conversion of derivative security	-	150,000 Added 11.58%	1,145,195 Common Stock
Mar 18 2025	SELL Open market or private sale	$22,593 $0.6 p/Share	37,656 Reduced 3.65%	995,195 Common Stock
Feb 04 2025	BUY Grant, award, or other acquisition	-	375,000 Added 26.64%	1,032,851 Common Stock
Aug 20 2024	SELL Open market or private sale	$17,094 $1.23 p/Share	13,898 Reduced 2.07%	657,851 Common Stock
Aug 20 2024	BUY Exercise of conversion of derivative security	-	37,500 Added 5.29%	671,749 Common Stock
Mar 26 2024	BUY Exercise of conversion of derivative security	$172,335 $1.57 p/Share	109,768 Added 14.75%	634,249 Common Stock
Mar 19 2024	SELL Open market or private sale	$42,266 $2.09 p/Share	20,223 Reduced 3.71%	524,481 Common Stock
Jan 18 2024	BUY Grant, award, or other acquisition	-	90,000 Added 14.18%	544,704 Common Stock
Dec 20 2023	SELL Open market or private sale	$18,700 $1.38 p/Share	13,551 Reduced 2.89%	454,704 Common Stock
Dec 17 2023	BUY Exercise of conversion of derivative security	-	37,500 Added 7.41%	468,255 Common Stock
Sep 22 2023	SELL Open market or private sale	$18,981 $1.3 p/Share	14,601 Reduced 3.28%	430,755 Common Stock
Sep 20 2023	BUY Grant, award, or other acquisition	-	40,000 Added 8.24%	445,356 Common Stock
May 19 2023	BUY Exercise of conversion of derivative security	$25,959 $1.57 p/Share	16,535 Added 3.92%	405,356 Common Stock
Mar 16 2023	SELL Open market or private sale	$13,387 $1.88 p/Share	7,121 Reduced 1.8%	388,821 Common Stock
Feb 02 2023	BUY Grant, award, or other acquisition	-	105,000 Added 20.96%	395,942 Common Stock
Jul 20 2022	SELL Open market or private sale	$21,174 $1.42 p/Share	14,911 Reduced 4.88%	290,942 Common Stock
Jul 19 2022	BUY Grant, award, or other acquisition	-	40,000 Added 11.57%	305,853 Common Stock
May 09 2022	BUY Exercise of conversion of derivative security	$85,475 $0.94 p/Share	90,931 Added 25.49%	265,853 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	75,000 Added 30.01%	174,922 Common Stock
Aug 11 2021	BUY Exercise of conversion of derivative security	$104,088 $1.13 p/Share	92,113 Added 47.97%	99,922 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	$42 $1.04 p/Share	40 Added 0.51%	7,849 Common Stock
Mar 31 2021	SELL Open market or private sale	$749,000 $7.49 p/Share	100,000 Reduced 32.58%	206,894 Common Stock
Mar 31 2021	BUY Exercise of conversion of derivative security	$113,000 $1.13 p/Share	100,000 Added 24.58%	306,894 Common Stock
Dec 23 2020	BUY Exercise of conversion of derivative security	$113,000 $1.13 p/Share	100,000 Added 32.58%	206,894 Common Stock

SAM

Sean A. Mc Carthy

CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTMX shares.

Notify only if

Value

Insider Trading

Get notified when an Cytom X Therapeutics, Inc. insider buys or sells CTMX shares.

Notify only if

Operation

Value

Type

News

Receive news related to CytomX Therapeutics, Inc.

Track Activities on CTMX

Account